William Blair Has Positive Outlook for Xencor Q3 Earnings

Xencor, Inc. (NASDAQ:XNCR) – Research analysts at William Blair upped their Q3 2025 earnings estimates for shares of Xencor in a report issued on Wednesday, August 6th. William Blair analyst M. Phipps now anticipates that the biopharmaceutical company will post earnings per share of ($0.83) for the quarter, up from their prior forecast of ($0.89). William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Xencor’s current full-year earnings is ($3.68) per share. William Blair also issued estimates for Xencor’s Q4 2025 earnings at ($0.92) EPS, FY2025 earnings at ($2.83) EPS, Q1 2026 earnings at ($0.90) EPS, Q2 2026 earnings at ($0.85) EPS, Q3 2026 earnings at ($0.83) EPS, Q4 2026 earnings at ($0.81) EPS, FY2026 earnings at ($3.39) EPS, FY2027 earnings at ($3.24) EPS and FY2028 earnings at ($3.34) EPS.

A number of other research firms have also recently weighed in on XNCR. Wells Fargo & Company lowered their price objective on shares of Xencor from $33.00 to $27.00 and set an “overweight” rating for the company in a research report on Thursday, August 7th. Wedbush lowered their price objective on shares of Xencor from $31.00 to $26.00 and set an “outperform” rating for the company in a research report on Thursday, August 7th. Finally, Barclays lowered their price objective on shares of Xencor from $22.00 to $6.00 and set an “underweight” rating for the company in a research report on Thursday, May 8th. Two research analysts have rated the stock with a sell rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $26.43.

Xencor Price Performance

Shares of NASDAQ XNCR opened at $7.00 on Monday. The company has a market capitalization of $499.24 million, a P/E ratio of -2.92 and a beta of 0.89. The company has a 50 day simple moving average of $8.64 and a 200-day simple moving average of $10.78. Xencor has a 1 year low of $6.92 and a 1 year high of $27.24.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.37. The business had revenue of $43.61 million during the quarter, compared to the consensus estimate of $22.59 million. Xencor had a negative net margin of 121.52% and a negative return on equity of 25.75%. The business’s revenue was up 82.4% compared to the same quarter last year. During the same quarter last year, the firm earned ($1.07) EPS.

Insider Buying and Selling at Xencor

In other Xencor news, Director Richard J. Ranieri sold 2,993 shares of the firm’s stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $9.22, for a total value of $27,595.46. Following the completion of the transaction, the director owned 19,183 shares of the company’s stock, valued at $176,867.26. This trade represents a 13.50% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Ellen Feigal sold 2,993 shares of the firm’s stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $9.22, for a total transaction of $27,595.46. Following the completion of the transaction, the director directly owned 19,183 shares of the company’s stock, valued at $176,867.26. This represents a 13.50% decrease in their position. The disclosure for this sale can be found here. Insiders sold 11,194 shares of company stock valued at $103,209 in the last 90 days. Company insiders own 5.23% of the company’s stock.

Hedge Funds Weigh In On Xencor

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Sterling Capital Management LLC boosted its position in Xencor by 732.4% in the 4th quarter. Sterling Capital Management LLC now owns 1,182 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 1,040 shares during the period. GF Fund Management CO. LTD. purchased a new position in Xencor in the 4th quarter valued at approximately $34,000. State of Wyoming purchased a new position in Xencor in the 1st quarter valued at approximately $34,000. CWM LLC boosted its position in Xencor by 195.5% in the 1st quarter. CWM LLC now owns 3,372 shares of the biopharmaceutical company’s stock valued at $36,000 after buying an additional 2,231 shares during the period. Finally, Mackenzie Financial Corp purchased a new position in Xencor in the 4th quarter valued at approximately $101,000.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.